Ondansetron 4MG and 8MG
ID: SPE2D223R0007Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/78991b7acb26473fb3df647f2a7cc6a8/view
Timeline
    Description

    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ondansetron. This contract will establish a national supply source to provide Ondansetron HCL 4 and 8MG Tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The projected solicitation date is March of 2023.

    Lifecycle
    Title
    Type
    Ondansetron 4MG and 8MG
    Currently viewing
    Presolicitation
    Similar Opportunities
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Ibuprofen 400MG/600MG/800MG Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Trazodone tablets in various dosages and bottle counts. This procurement aims to secure a substantial quantity of pharmaceutical supplies essential for military and healthcare operations. Offerors are required to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries regarding the solicitation.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Buprenorphine Pre-solicitation notice
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking suppliers for Buprenorphine HCL/Naloxone HCL Sublingual Tablets, as outlined in the pre-solicitation notice VA797E26R0004. The procurement aims to establish a reliable supply source for federal healthcare programs, including the VA, DoD, IHS, and BOP, with a contract consisting of a one-year base period and four one-year option periods. These medications are critical for treating opioid dependence, and offerors must provide pricing for specific tablet strengths, comply with FDA manufacturing standards, and submit a Letter of Commitment from the manufacturer. Interested parties should contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further details, as compliance with various regulatory requirements and timely submission of quarterly sales reports will be essential for successful participation in this opportunity.
    Tretinoin Cream
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Tretinoin Cream. The cream is used for various dermatological conditions and comes in different strengths (0.025%, 0.05%, and 0.1%) and tube sizes (20G and 45G). The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. It will establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. Interested parties should contact Ryan Ferry for more information. The projected solicitation date is February 2023.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program, ensuring the selection of clinically and cost-effective pharmaceutical agents for inclusion in the DoD Uniform Formulary, particularly focusing on oncological agents for myelofibrosis, such as Inrebic, Jakafi, Ojjaara, and Vonjo. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025, and can direct inquiries to Tracy Banks or Stephanie Erpelding via their provided emails.
    Acquisition of Radioactive products (PLUVICTO and LUTATHERA)
    Dept Of Defense
    The Defense Health Agency (DHA) is planning to award a Firm-Fixed Price contract for the acquisition of radioactive products, specifically PLUVICTO and LUTATHERA, which are essential for imaging patients' diseases. These products must be U.S. FDA Approved and are to be supplied by Novartis Pharmaceuticals Corporation, the designated manufacturer. The total estimated cost for this procurement is $578,754.32, and interested parties are invited to express their interest and submit a capabilities statement by January 11, 2026, at 7:00 AM EST. For further inquiries, Malcolm Dodson can be contacted at malcolm.dodson.ctr@mail.mil or by phone at 703-275-6322.